This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary FGF-1 Therapeutic Antibody Development
FGF-1 plays a crucial role in various companion animal tumor growth processes, making it a popular target for drug research and development. The development of therapeutic antibodies targeting specific markers is demonstrating great potential in the current veterinary field. BioVenic offers comprehensive veterinary FGF-1 therapeutic antibody development services. From gene synthesis and antibody preparation to subsequent purification and validation, our services cover the entire development process, assisting in bringing innovative treatments for diseases in companion animals.
Background of FGF-1
| Full Name | Fibroblast growth factor 1 |
|---|---|
| Aliases | AFGF, ECGF, ECGFA, ECGFB, ECGF-beta, FGF-1, FGFA, FGF-alpha, GLIO703, HBGF1, HBGF-1. |
| Target Profile | FGF-1 is a member of the fibroblast growth factor family. Cells from three germ layers, including ectoderm, mesoderm, and endoderm, can express FGF-1, which stimulates their proliferation. Its biological effects are very broad, playing a significant role in tissue and organ development, angiogenesis, hematopoiesis, tumor occurrence, and wound healing. FGF-1 not only functions extracellularly through intracellular signaling pathways but can also enter cells to exert its biological functions. |
MoA of FGF-1
The interaction of FGF-1 with its specific receptors leads to receptor dimerization and activation, subsequently triggering a cascade of signals such as the MAPK/ERK and PI3K/AKT pathways. FGFR-dependent downstream signaling regulates cell differentiation, migration, apoptosis, and the cell cycle, and thus, dysregulation of the FGFR axis often leads to various systemic diseases. In cancer and other diseases, abnormal expression or activation of FGF-1 can lead to the development of pathological states. Cancer-associated fibroblasts (CAFs) secrete a plethora of growth factors into the tumor microenvironment, stimulating adhesion, motility, and evasion of local growth control. FGF-1 is one of the growth factors secreted by CAFs, which executes multiple functions through binding and activating members of FGFR4, such as cell survival, proliferation, and migration in various cell types.
Application in Veterinary Therapeutics
FGF-1 as a target holds significant potential in the treatment of cancer in companion animals like feline, canine, and equine. Therapeutic antibodies targeting FGF-1 can specifically bind to the FGF-1 molecule, preventing its interaction with the fibroblast growth factor receptors (FGFR) on the cell surface. This blockade can inhibit the signaling pathways activated by FGF-1, potentially restricting tumor growth and metastasis and promoting tumor apoptosis. Additionally, FGF-1 is one of the key factors in angiogenesis. By inhibiting FGF-1, therapeutic antibodies may reduce the formation of blood vessels in the tumor, limiting its access to nutrients and oxygen, and thereby inhibiting tumor growth.
Fig.1 Schematic diagram of FGF-1 activity blocked by specific antibody fragment ligands. 1,2
Veterinary FGF-1 Therapeutic Antibody Development Services
BioVenic is dedicated to providing the services for developing therapeutic antibodies targeting FGF-1 for use in companion animals like feline, canine, and equine, addressing significant diseases such as cancer. Our service encompasses the entire process from gene synthesis to the final antibody product, including antibody design, preparation, purification, and detailed bioactivity validation. Our team employs state-of-the-art technologies, such as hybridoma technology, single B-cell technology, and phage display technology, to ensure antibody production with high affinity and specificity. Additionally, our antibody engineering services include affinity maturation and species-specific antibody development, offering customized solutions to meet the specific treatment needs of different companion animals.
To learn more about our veterinary FGF-1 therapeutic antibody development services, please click the link below.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
With our expertise in animal immunization, gene synthesis, cell line development and cultivation, media optimization, antibody purification, and characterization, BioVenic offers tailored and comprehensive solutions for veterinary therapeutic antibody development.
Through CDR grafting technology, we achieve antibody caninization or felinization and optimize affinity maturation to provide you with high-affinity veterinary therapeutic antibodies tailored to meet the desired therapeutic functions.
We have established a platform for the development of veterinary therapeutic bispecific antibodies, assisting you in creating high-quality bispecific antibodies with structures similar in size to natural antibodies.
FGF-1 is expressed in various tissues within the animal body and plays a key role in cell proliferation, differentiation, and tissue repair. Its abnormal activation can significantly impact the growth and proliferation of tumors in companion animals. BioVenic offers veterinary FGF-1 therapeutic antibody development services, not only assisting in cancer treatment but also potentially extending to promoting wound healing and research on other related pathological conditions. If you are interested in our veterinary FGF-1 therapeutic antibody development services, please contact us for more information!
Reference
- Chudzian, Julia, et al., "Specific antibody fragment ligand traps blocking FGF1 activity." International Journal of Molecular Sciences 19.9 (2018): 2470.
- Image retrieved from "Graphical Abstract",Chudzian, Julia, et al. 2018, used under [CC BY 4.0], the image title was changed to " Schematic diagram of FGF-1 activity blocked by specific antibody fragment ligands."